日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial

来曲唑、阿贝西利和二甲双胍治疗子宫内膜癌:一项非随机 II 期试验

Konstantinopoulos, Panagiotis A; Zhou, Ningxuan; Penson, Richard T; Le, Tien V; Campos, Susana; Krasner, Carolyn; Wright, Alexi A; Porter, Rebecca; Horowitz, Neil; Bouberhan, Sara; Liu, Joyce F; Hindenach, Sarah; Sawyer, Hannah; Koppermann, Lani; Hayes, Martin; Polak, Madeline; Shea, Meghan; Widick, Page; Cheng, Su-Chun; Castro, Cesar; Beumer, Jan H; Matulonis, Ursula A; Lee, Elizabeth K

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

一项针对转移性激素受体阳性乳腺癌或晚期卵巢癌患者的I期研究,评估了ribociclib(CDK4/6抑制剂)联合spartalizumab(PD-1抑制剂)以及单独使用或不联合fulvestrant的疗效。

Ana C Garrido-Castro ,Noah Graham ,Lestat R Ali ,Christina Herold ,Jennifer Desrosiers ,Khanh Do ,Heather Parsons ,Tianyu Li ,Shom Goel ,Molly DiLullo ,Eileen Wrabel ,Amy J Williams ,Joyce F Liu ,Elizabeth A Mittendorf ,Stephanie K Dougan ,Nabihah Tayob ,Geoffrey I Shapiro ,Sara M Tolaney

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

比较度伐利尤单抗、奥拉帕尼和西地尼布单药治疗、联合治疗或化疗治疗既往接受过贝伐珠单抗治疗的铂耐药卵巢癌患者的疗效:II期NRG-GY023试验

Lee, Jung-Min; Miller, Austin; Rose, Peter G; AlHilli, Mariam; Washington, Christina; John, Veena S; Shah, Chirag A; Matsuo, Koji; Siedel, Jean; Miller, David S; Hopp, Elizabeth E; O'Shea, Andrea; Chan, John K; Bradford, Leslie S; Morse, Christopher B; Nagel, Christa I; Rodabaugh, Kerry J; Kohn, Elise C; Moore, Kathleen N; Liu, Joyce F

Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma

Wee1抑制剂adavosertib治疗复发性子宫癌肉瘤的II期研究

Cham, Stephanie; Xiong, Niya; Tayob, Nabihah; Krasner, Carolyn; Wright, Alexi A; Lee, Elizabeth K; Sawyer, Hannah; Mathews, Cara; Konstantinopoulos, Panagiotis A; Matulonis, Ursula A; Liu, Joyce F

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study

鲁索替尼联合一线新辅助治疗晚期卵巢癌的I期和随机II期研究:NRG肿瘤协作组研究

Landen, Charles N; Buckanovich, Ronald J; Sill, Michael W; Mannel, Robert S; Walker, Joan L; DiSilvestro, Paul A; Mathews, Cara A; Mutch, David G; Hernandez, Marcia L; Martin, Lainie P; Bishop, Erin; Gill, Sarah E; Gordinier, Mary E; Burger, Robert A; Aghajanian, Carol; Liu, Joyce F; Moore, Kathleen N; Bookman, Michael A

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

纳维托克和曲美替尼联合抑制BCL-xL和MEK治疗KRAS或NRAS突变晚期实体瘤的I/II期研究

Corcoran, Ryan B; Do, Khanh T; Kim, Jeong E; Cleary, James M; Parikh, Aparna R; Yeku, Oladapo O; Xiong, Niya; Weekes, Colin D; Veneris, Jennifer; Ahronian, Leanne G; Mauri, Gianluca; Tian, Jun; Norden, Bryanna L; Michel, Alexa G; Van Seventer, Emily E; Siravegna, Giulia; Camphausen, Kyle; Chi, Gary; Fetter, Isobel J; Brugge, Joan S; Chen, Helen; Takebe, Naoko; Penson, Richard T; Juric, Dejan; Flaherty, Keith T; Sullivan, Ryan J; Clark, Jeffrey W; Heist, Rebecca S; Matulonis, Ursula A; Liu, Joyce F; Shapiro, Geoffrey I

Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses

吉西他滨联合或不联合ATR抑制剂Berzosertib治疗铂类耐药卵巢癌的随机II期研究:最终总生存期和生物标志物分析

Konstantinopoulos, Panagiotis A; Cheng, Su-Chun; Lee, Elizabeth K; da Costa, Alexandre André B A; Gulhan, Doga; Wahner Hendrickson, Andrea E; Kochupurakkal, Bose; Kolin, David L; Kohn, Elise C; Liu, Joyce F; Penson, Richard T; Stover, Elizabeth H; Curtis, Jennifer; Sawyer, Hannah; Polak, Madeline; Chowdhury, Dipanjan; D'Andrea, Alan D; Färkkilä, Anniina; Shapiro, Geoffrey I; Matulonis, Ursula A

Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial

尼拉帕尼、多斯塔利单抗和贝伐珠单抗联合治疗既往接受过治疗的晚期铂耐药卵巢癌:OPAL II期试验A组队列的研究结果

Liu, Joyce F; Gaillard, Stéphanie; Wahner Hendrickson, Andrea E; Yeku, Oladapo; Diver, Elisabeth; Gunderson Jackson, Camille; Arend, Rebecca; Ratner, Elena; Samnotra, Vivek; Gupta, Divya; Chung, Jon; Zhang, Hailei; Compton, Natalie; Baines, Amanda; Bacqué, Emeline; Liu, Xiaohong; Felicetti, Brunella; Konecny, Gottfried E

Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysis

改善腹膜癌患者姑息治疗决策流程:一项二次分析

Wall, Jaclyn A; Pozzar, Rachel A; Enzinger, Andrea C; Tavormina, Anna; Howard, Catherine; Matulonis, Ursula A; Liu, Joyce F; Horowitz, Neil; Meyer, Larissa A; Wright, Alexi A

A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib

一项 II 期试验旨在探讨同源重组状态在接受西地尼布和奥拉帕尼联合治疗的铂敏感或铂耐药复发性卵巢癌患者中的意义。

Liu, Joyce F; Xiong, Niya; Wenham, Robert M; Wahner-Hendrickson, Andrea; Armstrong, Deborah K; Chan, Nancy; O'Malley, David M; Lee, Jung-Min; Penson, Richard T; Cristea, Mihaela C; Abbruzzese, James L; Matsuo, Koji; Olawaiye, Alexander B; Barry, William T; Cheng, Su-Chun; Polak, Madeline; Swisher, Elizabeth M; Shapiro, Geoffrey I; Kohn, Elise C; Ivy, S Percy; Matulonis, Ursula A